Advertisement

Topics

Valchlor (mechlorethamine)

15:49 EST 24th November 2017 | BioPortfolio

VALCHLOR, a gel which is applied topically once a day, is an alkylating drug indicated to treat patients with stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) who have received prior skin-directed therapy. VALCHLOR is an orphan drug that was acquired by Actelion US Holding Company, a subsidiary of Actelion Ltd., on September 18, 2013 as part of a merger with Ceptaris Therapeutics, Inc. VALCHLOR is distributed in the US by Accredo Specialty Pharmacy.

VALCHLOR (mechlorethamine) gel 0.016% is an alkylating drug indicated for the topical treatment of stage IA and IB mycosis fungoides-type cutaneous T-cell lymphoma (MF-CTCL) in patients who have received prior skin-directed therapy. VALCHLOR is a gel which is applied topically once a day. Mechlorethamine, commonly known as nitrogen mustard, is a chemotherapeutic agent previously approved for intravenous treatment of mycosis fungoides, the most common type of cutaneous T-Cell lymphoma. Mechlorethamine is one of the suggested skin-directed treatment regimens for early-stage MF-CTCL according to the latest National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology (NCCN Guidelines®)[1]. VALCHLOR is the first and only FDA-approved topical formulation of mechlorethamine.

For more information and full prescribing information visit www.valchlor.com

Quick Search
Advertisement
 

review and buy Valchlor (mechlorethamine) market research data and corporate reports here